SOD1 ALS Gene Therapy

About Voyager Therapeutics

Voyager Therapeutics is dedicated to developing transformative gene therapies for neurological disorders by leveraging human genetics and its proprietary TRACER™ capsid discovery platform. The company's strategy combines internal pipeline development with strategic platform collaborations to de-risk R&D and generate non-dilutive funding. Key achievements include the generation of novel, IV-administered capsids with enhanced brain tropism and a pipeline featuring multiple preclinical and IND-enabling programs for high-need conditions like Alzheimer's and ALS.

Therapeutic Areas